The role of molecular markers in the staging of renal cell carcinoma

BJU International

Volumn 99, Issue 5 B, 2007, Pages 1208-1211

  Leppert, John T ^a   Pantuck, Allan J ^a   Figlin, Robert A ^a   Belldegrun, Arie S ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Kidney cancer; Molecular markers; Prognosis; Staging

Indexed keywords

MOLECULAR MARKER;

CANCER STAGING; GENE EXPRESSION; HUMAN; IMMUNOTHERAPY; KIDNEY CARCINOMA; MOLECULAR DYNAMICS; POSTOPERATIVE PERIOD; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; REVIEW;

CARCINOMA, RENAL CELL; GENE EXPRESSION PROFILING; HUMANS; IMMUNOTHERAPY; KIDNEY NEOPLASMS; NEOPLASM STAGING; PROGNOSIS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL;

EID: 34247203754     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2007.06812.x     Document Type: Review

References (33)

1. Jemal A, Siegel R, Ward E et al. Cancer statistics, 2006. CA Cancer J Clin 2006; 56: 106-30
2. Lam JS, Shvarts O, Leppert JT, Figlin RA, Belldegrun AS. Renal cell carcinoma 2005: new frontiers in staging, prognostication and targeted molecular therapy. J Urol 2005; 173: 1853-62
3. Janzen NK, Kim HL, Figlin RA, Belldegrun AS. Surveillance after radical or partial nephrectomy for localized renal cell carcinoma and management of recurrent disease. Urol Clin North Am 2003; 30: 843-52
4. Leibovich BC, Pantuck AJ, Bui MH et al. Current staging of renal cell carcinoma. Urol Clin North Am 2003; 30: 481-97
5. Flocks RH, Kadesky MC. Malignant neoplasms of the kidney; an analysis of 353 patients followed five years or more. J Urol 1958; 79: 196-201
6. Robson CJ, Churchill BM, Anderson W. The results of radical nephrectomy for renal cell carcinoma. J Urol 1969; 101: 297-301
7. Guinan P, Sobin LH, Algaba F et al. TNM staging of renal cell carcinoma: Workgroup No. 3. Union International Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer 1997; 80: 992-3
8. Zisman A, Pantuck AJ, Dorey F et al. Improved prognostication of renal cell carcinoma using an integrated staging system. J Clin Oncol 2001; 19: 1649-57
9. Kattan MW, Reuter V, Motzer RJ, Katz J, Russo P. A postoperative prognostic nomogram for renal cell carcinoma. J Urol 2001; 166: 63-7
10. Patard JJ, Kim HL, Lam JS et al. Use of the University of California Los Angeles integrated staging system to predict survival in renal cell carcinoma: an international multicenter study. J Clin Oncol 2004; 22: 3316-22
11. Cindolo L, Patard JJ, Chiodini P et al. Comparison of predictive accuracy of four prognostic models for nonmetastatic renal cell carcinoma after nephrectomy: a multicenter European study. Cancer 2005; 104: 1362-71
12. Uemura H, Nakagawa Y, Yoshida K et al. MN/CA IX/G250 as a potential target for immunotherapy of renal cell carcinomas. Br J Cancer 1999; 81: 741-6
13. Bui MH, Seligson D, Han KR et al. Carbonic anhydrase IX is an independent predictor of survival in advanced renal clear cell carcinoma: implications for prognosis and therapy. Clin Cancer Res 2003; 9: 802-11
14. Mulders P, Bleumer I, Debruyne F, Oosterwijk E. Specific monoclonal antibody-based immunotherapy by targeting the RCC-associated antigen carbonic anhydrase-IX (G250/MN). Urologe A 2004; 43(Suppl. 3): 146-7
15. Lam JS, Leppert JT, Figlin RA, Belldegrun AS. Role of molecular markers in the diagnosis and therapy of renal cell carcinoma. Urology 2005; 66(Suppl.): 1-9
16. Kim HL, Seligson D, Liu X et al. Using protein expressions to predict survival in clear cell renal carcinoma. Clin Cancer Res 2004; 10: 5464-71
17. Kim HL, Seligson D, Liu X et al. Using tumor markers to predict the survival of patients with metastatic renal cell carcinoma. J Urol 2005; 173: 1496-501
18. Takahashi M, Rhodes DR, Furge KA et al. Gene expression profiling of clear cell renal cell carcinoma: gene identification and prognostic classification. Proc Natl Acad Sci USA 2001; 98: 9754-9
19. Takahashi M, Yang XJ, Sugimura J et al. Molecular subclassification of kidney tumors and the discovery of new diagnostic markers. Oncogene 2003; 22: 6810-8
20. Jones J, Otu H, Spentzos D et al. Gene signatures of progression and metastasis in renal cell cancer. Clin Cancer Res 2005; 11: 5730-9
21. Vasselli JR, Shih JH, Iyengar SR et al. Predicting survival in patients with metastatic kidney cancer by gene-expression profiling in the primary tumor. Proc Natl Acad Sci USA 2003; 100: 6958-63
22. Tan M. Gene expression profiling predicts survival in clear cell renal cell carcinoma. J Clin Oncol 2005; 23: 4534
23. Kosari F, Parker AS, Kube DM et al. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin Cancer Res 2005; 11: 5128-39
24. Yang JC, Sherry RM, Steinberg SM et al. Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer. J Clin Oncol 2003; 21: 3127-32
25. Upton MP, Parker RA, Youmans A, McDermott DF, Atkins MB. Histologic predictors of renal cell carcinoma response to interleukin-2-based therapy. J Immunother 2005; 28: 488-95
26. Atkins M, Regan M, McDermott D et al. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer. Clin Cancer Res 2005; 11: 3714-21
27. Pantuck AJ, Liu X, Seligson DB et al. Gene expression and tissue microarray analysis of interleukin-2 complete responders in patients with metastatic renal cell carcinoma. J Clin Oncol 2005; 23: 4535
28. Leppert JT, Lam JS, Yu H et al. Targeting the vascular endothelial growth factor pathway in renal cell carcinoma: a tissue array based analysis. J Clin Oncol 2005; 23: 4536
29. Skubitz KM, Skubitz AP. Differential gene expression in renal-cell cancer. J Lab Clin Med 2002; 140: 52-64
30. Young AN, Amin MB, Moreno CS et al. Expression profiling of renal epithelial neoplasms: a method for tumor classification and discovery of diagnostic molecular markers. Am J Pathol 2001; 158: 1639-51
31. Yang JC. Bevacizumab for patients with metastatic renal cancer: an update. Clin Cancer Res 2004; 10: 6367-70S
32. Yang JC, Haworth L, Sherry RM et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med 2003; 349: 427-34
33. Rini BI, Small EJ. Biology and clinical development of vascular endothelial growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 2005; 23: 1028-43